Simcere Pharmaceutical Group Ltd. (2096.HK) announced on Friday that it has entered into a research collaboration agreement with Stanford Medicine to develop a treatment for irreversible Idiopathic Pulmonary Fibrosis or IPF, a chronic lung disease of unknown origin and with no known cure. Under the...
The Democratic Republic of Congo (DRC) saw an outbreak of Ebola last month, with a significant case count and rising death toll reported from the region. The United Nations declared a Public Health Emergency of International Concern in the DRC and Uganda, and has amplified efforts to protect vulnerable...
Viking Therapeutics, Inc. (VKTX), a clinical-stage biopharmaceutical company, Thursday announced that it has appointed Hubert Chen, as its Chief Medical Officer. Chen brings more than two decades of leadership experience in senior executive roles spanning drug discovery, clinical development, regulatory...
On Wednesday, CervoMed Inc. (CRVO), a biotechnology company specialized in brain disorder treatment, announced that it has entered into a definitive securities purchase agreement for a private placement, expecting gross proceeds of approximately $10.5 million. Each unit includes either one share of...
Genmab A/S (GMAB) on Thursday presented new subgroup data from the Phase 3 EPCORE FL-1 trial showing that epcoritamab in combination with rituximab and lenalidomide (R2) delivered consistent efficacy and a manageable safety profile across multiple patient subgroups with relapsed or refractory follicular...
Humacyte, Inc. (HUMA) shares plunged 23.05 percent, losing $0.31 to $1.03 on Thursday, likely extending losses following the company's announcement yesterday, of a public offering of 47.62 million shares of common stock priced at $1.05 per share.
BioCryst Pharmmaceuticals Inc. (BCRX), a biotechnology company, on Friday released new data from the real-world APeX-P study for ORLADEYO and the Phase 1b/2 ALPHA-STAR for Navenibart in treating hereditary angioedema. ORLADEYO (berotralstat) is an oral prophylactic therapy that increases plasma kallikrein...
Kyntra Bio (KYNB), a biopharmaceutical company, on Thursday released new data from the Phase 3 MATTERHORN trial for Roxadustat in treating anemia associated with lower-risk myelodysplastic syndrome. Myelodysplastic syndromes (MDS) are characterized by dysfunctional progenitor blood cells and stem...
Friday, Jazz Pharmaceuticals plc (JAZZ) announced that the Phase 3 LAGOON trial, evaluating Zepzelca (lurbinectedin) in patients with relapsed metastatic small cell lung cancer, did not meet its primary endpoint of overall survival. The trial, conducted by , comprised of three arms: one arm to receive...
Novartis AG (NVS) on Thursday presented data from the Phase III RemIND trial at the European Academy of Allergy and Clinical Immunology (EAACI) Congress, highlighting the efficacy and safety of Rhapsido in chronic inducible urticaria (CIndU). The RemIND trial met its primary endpoints across the three...
GSK plc (GSK, GSK.L) announced that momelotinib has received Orphan Drug Designation from the FDA and European Medicines Agency for the treatment of VEXAS syndrome. The company said the planned phase II/III ATLAS trial will evaluate momelotinib's efficacy and safety in VEXAS syndrome and will support...
June's FDA calendar offers plenty for investors to keep a close eye on. Among the key names are Spero Therapeutics, awaiting an FDA decision on its antibiotic for complicated urinary tract infections; Kiniksa Pharma, seeking approval for a technology transfer of the manufacturing process for Arcalyst drug substance; and Merck, pursuing the first FDA approval for its WELIREG - KEYTRUDA combination.
March 31, 2026 15:49 ET In this week’s video, we’ll cover major biotech moves and breakthroughs - from Novartis and Merck’s blockbuster acquisitions to the first new Hunter syndrome therapy in two decades. We’ll also look at a promising alternative to daily insulin injections and the near-term catalyst for Q3 Bio, which has been hitting new 52-week highs.
Retailer Target Corp. is recalling select Up & Up Baby Wipes, due to potential microbial contamination, according to the U.S. Food and Drug Administration. The recall involves Up & Up FragranceFree Baby Wipes and Up & Up Fresh Cucumber Scented Baby Wipes with various counts and UPC numbers. The impacted wipes were manufactured by a supplier, Sapro Temizlik Urunleri, and sold at Target stores...
a2 Milk Company Ltd. (ACOPF, A2M.AX), a dairy company, announced a recall of select infant milk formula, manufactured by Synlait Milk Limited and sold only in the United States, citing the presence of cereulide. The recall involves three batches of a2 Platinum USA label infant milk formula, comprising...
A child's family income and the neighborhood they grow up in may play a much bigger role in brain development than previously believed, according to a new study published in Science. Researchers at Washington University in the United States analyzed brain scans from nearly 12,000 children aged 9 to...
A new Canadian study has found that social anxiety disorder (SAD) affects nearly one in seven adults, making it one of the country's most common mental health conditions. The findings, published in Psychiatry Research, showed that the number of people experiencing social anxiety has increased by 71%...
A new review suggests that music therapy may offer meaningful benefits for people living with neurological, psychiatric, and chronic health conditions, but its wider adoption in clinical practice continues to be limited by workforce shortages, inconsistent standards, and gaps in research.
Researchers at the University of Cambridge have achieved a major milestone in vaccine development by successfully testing an artificial intelligence (AI)-designed universal coronavirus vaccine in humans for the first time. Early results show that the vaccine is safe, well tolerated, and capable of generating...
Cullinan Therapeutics Inc. (CGEM), a clinical-stage biopharmaceutical company, is scheduled to host an Immunology Day tomorrow, i.e., June 10, 2026. When we alerted readers to CGEM on June 29, 2025, it was at $7.93. The stock, which touched a high of $16.74 on February 27, 2026, has given back some of its gains and currently trades around $13.